Tenofovir/Emtricitabine — Competitive Intelligence Brief

Tenofovir/Emtricitabine (Tenofovir/Emtricitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination. Area: Infectious Disease / Virology.

marketed Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Tenofovir/Emtricitabine (Tenofovir/Emtricitabine) — Bristol-Myers Squibb. Tenofovir and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tenofovir/Emtricitabine TARGET	Tenofovir/Emtricitabine	Bristol-Myers Squibb	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
"Raltegravir" and "Zidovudine"	"Raltegravir" and "Zidovudine"	Universidad Peruana Cayetano Heredia	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitor)	HIV integrase (raltegravir); HIV reverse transcriptase (zidovudine)
BIC/FTC/TAF	BIC/FTC/TAF	Prism Health North Texas	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	University of British Columbia	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
LPV/r + TDF/FTC or TDF/3TC	LPV/r + TDF/FTC or TDF/3TC	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Vaginal TFV Gel	Vaginal TFV Gel	University of Washington	marketed	Nucleotide reverse transcriptase inhibitor (microbicide)	HIV reverse transcriptase
Standard-of-care Antiretroviral therapy	Standard-of-care Antiretroviral therapy	Medical Research Council	marketed	Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination class)

1. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
2. Bristol-Myers Squibb · 1 drug in this class
3. Puerto Rico Community Network for Clinical Research on AIDS · 1 drug in this class
4. The Miriam Hospital · 1 drug in this class